Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications.

Patients with hematological malignancies frequently suffer from lung diseases as a complication. However, it is difficult to discriminate leukemic invasion into the lung from infectious pulmonary complications. The serum level of Krebs von den Lungen-6 (KL-6), which is a mucin-like glycoprotein, is increased in more than 70% of patients with interstitial pneumonia. Surfactant protein-D (SP-D) is produced mainly in the lung by alveolar type II and bronchiolar epithelial cells and is a useful serum marker for interstitial pneumonia. We therefore measured the levels of KL-6 and SP-D in sera from 128 patients (76 males and 52 females, mean age: 59 years) with hematological malignancies, including adult T-cell leukemia (ATL). Overall, the increase in KL-6 or SP-D, above each cut-off value (500 U/ml for KL-6 and 110 ng/ml for SP-D), was detected in 11 patients (8.6%) or 10 patients (7.8%), respectively. In contrast, among 67 ATL patients, 15 patients had high serum levels of KL-6 and/or SP-D; both were elevated in 2 patients, only KL-6 was elevated in 6 patients and only SP-D was elevated in 7 patients. Thus, serum KL-6 and SP-D appear to be elevated in a mutually exclusive manner in ATL. Indeed, high serum levels of KL-6 were closely related to the stage of ATL, while the serum SP-D was elevated in ATL patients with pulmonary infection. In conclusion, the combined measurement of KL-6 and SP-D in ATL may become a useful means to discriminate leukemic pulmonary lesions from infectious pulmonary complications.

[1]  K. Chida,et al.  Peripheral T‐cell lymphoma with diffuse pulmonary infiltration and an increase in serum KL‐6 level , 2007, Respirology.

[2]  G. Basu,et al.  MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells , 2005, Journal of leukocyte biology.

[3]  U. Holmskov,et al.  Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. , 2003, Clinical immunology.

[4]  A. Zelenetz,et al.  MUC-1 Mucin Protein Expression in B-cell Lymphomas , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  C. Bertozzi,et al.  Recent advances in the chemical synthesis of mucin-like glycoproteins. , 2002, Glycobiology.

[6]  K. Oizumi,et al.  Elevation of Serum KL-6 Levels in Patients with Hematological Malignancies Associated with Cytomegalovirus or Pneumocystis carinii Pneumonia , 2002, Hematology.

[7]  L. Kanz,et al.  The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. , 2001, Cancer research.

[8]  T. Nakahata,et al.  Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia. , 2001, Journal of medicine.

[9]  N. Kohno,et al.  Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. , 1999, The journal of medical investigation : JMI.

[10]  T. Waldmann,et al.  Infectious complications and immunodeficiency in patients with human T‐cell lymphotropic virus I‐associated adult T‐cell leukemia/lymphoma , 1995, Cancer.

[11]  M. Tomonaga,et al.  Significance of soluble interleukin‐2 receptor levels for evaluation of the progression of adult T‐cell leukemia , 1994, Cancer.

[12]  W. Gilks,et al.  Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[13]  N. Kohno,et al.  Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. , 1992, Chest.

[14]  N. Kohno,et al.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.